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detection of particle traverse within colony-initiating cells at 
subcellular resolution using Cell-FIT-HD. The current work 
represents a proof of principle study for correlation of 
particle traversal with long term colony formation using Cell-
FIT-HD. The entire workflow is established and builds a solid 
foundation for further improvements towards population 
level quantitative analysis.  
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Introduction: The positron-emitter 43Sc is considered to be an 
attractive PET radionuclidic alternative to 44Sc, due to its 
more favourable decay properties. What is more, the lower 
energetic gamma line will result in a lower radiation dose 
burden to the patient and the operator.[1] Together with 
47Sc, which demonstrates therapeutic effect by emitting soft 
β--particles, it can be considered as part of the “matched 
pair” principle, enabling tumour imaging and, following that, 
optimal therapy planning. The production of 43Sc is described 
by different nuclear reactions in literature: 43Ca(p,n)43Sc and 
46Ti(p,α)43Sc [1-3]. The feasibility of both production paths 
was tested at the PSI Injector II cyclotron. 
Materials and Methods: 43Ca and 46Ti targets were prepared 
by mixing enriched 43CaCO3 or 46Ti powder with graphite 
powder, pressed and encapsulated in aluminium. Since 
enriched Ti is only available in oxide form, the reduction of 
46TiO2 to elemental 46Ti powder was performed [4]. The 
43CaCO3 and 46Ti targets were irradiated with protons at 
different energies. Two different chromatographic separation 
methods were used to separate the 43Sc product from the 
respective target material. 
Results: The production of 43Ca(p,n)43Sc yields 43Sc with a 
radionuclidic purity of 66% ,while 44Sc was co-produced with 
33% at the end of separation (EOS). The produced 43Sc was 
used to perform a PET phantom study, indicating promising 
preliminary results for 43Sc being a superior imaging 
radionuclide to its 44Sc counterpart. The labelling of the 
obtained 43Sc with DOTANOC could be performed at a 
maximum specificity of 7 MBq 43Sc/nmol DOTANOC with a 
radiochemical purity of 97 %.  
The production of 46Ti(p,α)43Sc yielded 43Sc of 98.7% 
radionuclidic purity at EOS. The percentage of 44Sc in the 
final product did not exceed 1.2%. The longer-lived 
impurities 44mSc, 46Sc and 48Sc were less than 0.04%. To obtain 
enriched 46Ti target material of higher purity, several 
parameters of the 46TiO2 reduction process, including the 
amount of reducing agent, temperature profile and reaction 
time, were altered. Initial difficulties with  the  processing  
of  the  irradiated  46Ti  target  were  addressed  by  changing  
the irradiation parameters to lower beam intensity and 
prolonged irradiation time. 
Conclusion: Successful production of 43Sc was achieved 
utilizing two activation methods, however, the  43Sc  yield  at  
end  of  bombardment  (EOB)  is  significantly  higher  with  
the 43Ca(p,n)43Sc production route. Nevertheless, the 
expensive target material and a 43Sc product of lower 
radionuclidic purity are drawbacks of this pathway. The 
46Ti(p,α)43Sc production method yields 43Sc of high 
radionuclidic purity. However, the 46Ti preparation of 
reduced target material proved to be labour intensive. The 
significantly lower 43Sc yield at EOB is the focus of further 
optimisation. 
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Microbeam Radiation Therapy (MRT) is a relatively new 
approach in radiation oncology exploiting the dose-volume 
effect by using orthovoltage X-rays on a microscopic scale 
[1]. Arrays of plane parallel beams of typically 50 µm width 
with spacings of a few hundred µm show extraordinary 
normal tissue sparing, while still being capable to ablate 
tumours in preclinical research [2]. 
Purpose: Organ motion has not been an issue in MRT, as long 
as preclinical research was carried out in small samples, such 
as cell cultures and rodents. The possible future treatment of 
human brain tumours using microbeam radiation however 
may be affected by cardio-synchronous tissue pulsation. This 
pulsation, with amplitudes in the order of 100 µm [3], 
induces translational movements of the brain tissue causing a 
blurring of the planned plane-parallel dose pattern of 
microbeams in case of extended exposure times. 
Method: A Monte Carlo study to quantify these effects was 
performed using the Geant4 toolkit. Dose was scored in a 
homogeneous cubic water phantom of 15 cm size on a grid 
with 5 µm resolution perpendicular to the beam. The 
sensitive volume was chosen to have an extension of 1 mm 
along the beam direction in 20 mm depth from the surface, 
which corresponds to the reference dosimetry conditions in 
MRT. The relative statistical uncertainty of the dose (1 
standard deviation) per voxel was between 1% and 1.5% in 
the peak region and between 6% and 9% in the dose valley, 
depending on the evaluated beam configuration and could be 
further reduced by appropriate binning of the raw data. 
Results: Monte Carlo calculations for different geometrical 
microbeam configurations and employed dose rates revealed 
significant changes of the planned dose patterns when 
compared to the static case. The chosen quality indicators of 
our study like peak dose, peak-to-valley dose ratio (PVDR), 
microbeam width, spacing, and penumbra were observed to 
be highly degraded, e.g. the PVDR being reduced by up to 
35%. 
Conclusions: We have demonstrated that the effect of even 
small organ motions occurring at heart rate frequencies in 
the brain can only be tolerated at high dose rates of approx. 
10 Gy/s. For example, a dose rate of 12.3 kGy/s can be given 
as a threshold value if one wants to apply a high peak 
entrance dose of 300 Gy in 3 mm depth for 50 µm wide 
microbeams and a primary beam size of 500 µm 
perpendicular to the scan direction.  For lower dose rates the 
observed deterioration of the microbeam dose patterns is 
likely to destroy the intended dose sparing effect for healthy 
tissues. 
For interlaced microbeam geometries an appropriate gating 
technique could be applied in the future based on the phase 
of the cardiac cycle. 
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Although radiotherapy (RT) is one of the major cancer 
treatment modalities to kill malignant cells, advanced-stage 
disease is often hard to control. Radiation-induced tumor cell 
death provides a plethora of pro-immunogenic effectors 
associated with inflammation. Although the potential for RT 
to generate anti-tumor immunity is apparent, the evidence 
that it does so in the clinical situation is limited. Stimulation 
of the immune system to assist in eliminating cancer cells 
within, and outside, the radiation field could be beneficial in 
advanced-stage or metastasized disease. Recently, it has 
been demonstrated that cancer patients have increased 
levels of cytotoxic T-cells after radiotherapy, making them 
eligible for immunotherapy. Interleukin-2 (IL2) is one of the 
essential cytokines for driving proliferation and 
differentiation of T-cells and NK-cells resulting in increased 
cytotoxic activity, eventually leading to tumor regression. 
Several studies have shown synergistic anti-tumor effects 
when combining RT with systemic IL2 administration, 
although this strategy was accompanied with severe adverse 
effects. 
Monoclonal antibodies, such as the human recombinant scFv 
fragment L19, have been designed as “targeting vehicle” for 
the selective delivery of immune-stimulatory cytokines to the 
tumor microenvironment while sparing normal tissue. The 
L19 antibody selectively localizes at the tumor neovascular 
fibronectin extra-domain B (EDB) positive sites following 
systemic administration and can serve as delivery vehicle for 
IL2. Our lab has combined single high-dose RT with systemic 
L19-IL2 administration in a number of murine xenograft 
models and found outstanding, long-lasting complete 
response rates mediated by cytotoxic CD8+ T-cell (1,2) or NK-
cell (3) activity depending on the tumor model. L19-IL2 is 
thus an immunocytokine with strong immune response 
enhancing properties in EDB-positive tumors. 
The combination therapy resulted also in anti-tumor immune 
effects outside the radiation field, an effect associated with 
CD4+ T-cell response. Growth of secondary un-irradiated 
tumors was significantly delayed with even 20% cure. Similar 
results were found when irradiation was delivered in a 
fractionated manner, although without resulting in cures. An 
increased PD-1 expression on T-cells infiltrating these tumors 
suggests a more regulatory immunological phenotype after 
fractionated radiotherapy compared with a single high RT 
dose. Re-challenging cured animals with tumor cells did not 
result in tumor formation, associated with high CD127 
expression. Our recent data show that radiotherapy 
combined with the immunocytokine L19-IL2 results in long-
lasting complete response rates, also outside the radiation 
field (abscopal effect) and this effect is associated with a 
memory potential. 
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Purpose: Tin-117m is a radionuclide of interest for cancer 
and cardiovascular disease therapies. It has a half-life of 13.6 
days and emits conversion and Auger electrons. It is actually 
used in clinical trials, where the radiopharmaceutical is 
developed by Clear Vascular Inc., to treat vulnerable plaque 
[1]. For this application, tin-117m is produced by the 
irradiation of Cd-116 enriched target with alpha particles. 
The goal of this study is to determine the irradiation 
conditions to get the highest specific activity of the final 
product, based on this reaction. 
Materials/methods: Tin-117m production study has been 
investigated at the ARRONAX [2] cyclotron (France) that is 
able to deliver alpha particles at 67.4 MeV. Production cross 
section measurements of tin-117m as well as radioactive 
contaminants have been made using the stacked-foils 
technique. It consists in the irradiation of a group of thin 
foils: target, monitor and degrader. The stacks were made of 
thin natural cadmium as targets and aluminum foils as 
degraders. Monitor foils acted also as catcher and were made 
of different material depending on the energy. After 
irradiation, the activity of each radionuclides produced in the 
foils has been determined by γ spectrometry [3]. Production 
of stable and long live isotopes has been estimated with the 
TALYS code [4]. From the cross section data, thick target 
production yields (TTY) have been calculated as well as tin-
117m specific activity (SA). 
Results: The production cross section values obtained for the 
Cd-116(α,x) reaction up to 65 MeV have been compared with 
the literature. From these data, Sn-117m TTY has been 
calculated considering a 100% Cd-116 enriched target. A TTY 
of 6.3 MBq/(µA.h) is obtained for 65 MeV alpha particles on a 
thick target. Our results are compared with the value 
reported by Clear Vascular Inc. at 47 MeV. A difference of 
only 6.3 % has been found. In order to determine the SA, the 
mass of stable and long live tin isotopes produced during the 
irradiation have been determined using the TALYS code. The 
figure 1 shows the tin-117m SA in kCi/g from 25 to 65 MeV. 
The maximum tin-117m SA is reached around 40 MeV with 41 
kCi/g and corresponds to a TTY of around 4 MBq/(µA.h). 
Clear Vascular Inc. reported a value of 25 kCi/g at 47 MeV. 
This value is 28 % lower than what is expected from our 
calculation.  
 
